Blog dermatologico
Elenco degli articoli con argomento «FDA»
2022
FDA approves Ruxolitinib
Pubblicazioni ScientificheThe Food and Drug Administration (FDA) has authorized Ruxolitinib (Opzelura)...
Leggi tutto2019
Italian guidelines in diagnosis and treatment of alopecia areata
Pubblicazioni ScientificheAlopecia Areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles....
Leggi tutto
2019
Psoriasi a placche, Fda approva farmaco per l'uso negli adolescenti dai 12 anni di età
Rassegna stampaLa Food and Drug Administration (FDA) degli Stati Uniti ha approvato calcipotriene 0,005% formulato in schiuma, commercializzato da Mayne Pharma Group, per il trattamento della psoriasi a placche del cuoio capelluto e del corpo negli a...
Leggi tutto2019
Brexit, anche la Fda si sposta da Londra ad Amsterdam
Rassegna stampaNon è escluso che gli uffici di rappresentanza della Food and drug administration nel Regno Unito si spostino in Olanda per mantenere la vicinanza con Ema...
Leggi tutto2017
Dermatite atopica, ecco le prospettive di trattamento più promettenti
Rassegna stampaStudi clinici hanno mostrato che l’uso di anticorpi monoclonali riesce a ridurre i gravi effetti di questa malattia cronica della pelle...
Leggi tutto2017
FDA Approves Dupilumab Injection for Atopic Dermatitis
Rassegna stampaThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) injection to treat adults with moderate-to-severe atopic dermatitis....
Leggi tutto2017
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
Rassegna stampaThe US Food and Drug Administration (FDA) has granted accelerated approval to avelumab (Bavencio) for the treatment of patients aged 12 years and older with metastatic Merkel cell carcinoma (MCC)....
Leggi tutto2017
FDA Approves Pembrolizumab for Certain Patients With Hodgkin Lymphoma
Rassegna stampaThe US Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after 3 ...
Leggi tutto2017
Topical Oxymetazoline 1.0% Shows Long-Term Efficacy for Persistent Facial Erythema Associated With Rosacea
Rassegna stampaPatients were able to tolerate treatment of their rosacea with topical 1% oxymetazoline hydrochloride gel for 1 year with acceptable reduction of redness and few adverse events, according to a study presented here at the 75th Annual Me...
Leggi tutto2017
FDA Approves Brodalumab to Treat Psoriasis
Rassegna stampaThe US Food and Drug Administration (FDA) has approved brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab is administered as an injection....
Leggi tutto2016
FDA Approves Crisaborole to Treat Atopic Dermatitis
Rassegna stampaThe US Food and Drug Administration (FDA) has approved crisaborole (Eucrisa) ointment to treat atopic dermatitis in patients aged 2 years and older....
Leggi tutto2016
FDA Evaluating the Risk of Burns, Scars With Sumatriptan Migraine Patch
Rassegna stampaThe US Food and Drug Administration (FDA) is investigating the risk of serious burns and potential permanent scarring with the use of sumatriptan iontophoretic transdermal system patch (Zecuity) for migraine headaches...
Leggi tutto2016
Fda approva reslizumab nel trattamento dell'asma grave
Rassegna stampaLa Food and Drug Administration (Fda) ha autorizzato l'uso di reslizumab nella terapia di mantenimento dell'asma grave in soggetti di 18 anni e più già in trattamento con altri farmaci...
Leggi tutto2016
FDA Approves Ixekizumab for Adults With Plaque Psoriasis
Rassegna stampaThe US Food and Drug Administration (FDA) has approved ixekizumab (Taltz) for the treatment of adults with moderate-to-severe plaque psoriasis...
Leggi tutto2015
FDA Approves Nivolumab for Patients With BRAF V600 Wild-Type Advanced Melanoma
Rassegna stampaThe US Food and Drug Administration (FDA) has granted accelerated approval to nivolumab (Opdivo) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma...
Leggi tutto2015
Methylphenidate Transdermal System May Cause Chemical Leukoderma, Warns FDA
Rassegna stampaThe US Food and Drug Administration (FDA) is warning that chemical leukoderma may occur with use of the methylphenidate transdermal system (Daytrana patch) for attention-deficit/hyperactivity disorder...
Leggi tutto2015
Blood Test for Patients on Acne Medication Deemed Unnecessary
Rassegna stampaFor young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense...
Leggi tutto2015
Melanoma. Nivolumab: il farmaco riceve l'approvazione accelerata dalla FDA
Rassegna stampaLa Food and Drug Administration (FDA - Agenzia per gli Alimenti e i Medicinali), l'ente regolatorio statunitense, ha fornito un'approvazione accelerata al farmaco Nivolumab, di Bristol-Myers Squibb, per uso endovenoso. L'accelerazione ...
Leggi tutto2014
Nivolumab for Advanced Melanoma
Rassegna stampaThe US Food and Drug Administration (FDA) today approved nivolumab (Opdivo) for the treatment of patients with unresectable or metastatic melanoma who no longer respond to other drugs...
Leggi tutto2014
FDA Warns of Rare But Potentially Fatal Skin Reactions With Use of Ziprasidone
Rassegna stampaThe US Food and Drug Administration (FDA) is warning healthcare professionals that the antipsychotic drug ziprasidone (Geodon) is associated with a rare but serious skin reaction that can progress to affect other parts of the body...
Leggi tutto